Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of the Treatment of Recurrent Primary or Secondary CNS Lymphoma With ALIMTA (Pemetrexed), a Novel Anti-Folate

NCT00916630 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT00916630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00916630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of the Treatment of Recurrent Primary or Secondary CNS Lymphoma With ALIMTA (Pemetrexed), a Novel Anti-Folate
Lead sponsor
Massachusetts General Hospital
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2009
Completion date
September 30, 2015
Enrollment
18 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

central nervous system lymphoma